Canadian Biopharmaceutical Opens Polish Subsidiary
September 30, 2013
Helix BioPharma, a Canadian biopharmaceutical company that is developing drugs for the prevention and treatment of cancer, has established a Polish subsidiary, Helix Polska, which will step up collaboration with Polish scientists on cancer research.
Robert Verhagen, CEO of Helix, said, “Establishing Helix Polska further strengthens Canadian-Polish relationships and scientific collaboration, which commenced in 2005 when Polish investors first became shareholders of Helix. We recognize that our relationship with the various leading Polish institutions is important to our success, and Helix Polska will allow us to more effectively communicate and interact with these groups.”
Helix is developing innovative products for the treatment and prevention of cancer based on its proprietary technologies. Helix’s product development initiatives are focused primarily on its new drug candidates L-DOS47 and Topical Interferon Alpha-2b.
Helix is currently conducting a clinical study in Poland with L-DOS47 in patients with lung cancer. The study is being conducted at three centers in Warsaw—the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology; the Military Institute of Medicine; and the National Tuberculosis and Lung Diseases Research Institute—as well as the Mazovian Center of Pulmonary Diseases and Tuberculosis in Otwock near Warsaw.
Polish scientists have made a significant contribution to the development of breakthrough Helix technology and related clinical research. “The tasks of Helix Polska will include establishing close cooperation with other scientists in Poland and expanding and stepping up the company’s research program,” said Dr. Marek Orłowski, chairman of the supervisory board at Helix Polska.